Table 1.
Characteristic | Patients, No. (%)a |
---|---|
Age, y | |
0–14 | 32 (1.4) |
15–34 | 500 (21.8) |
35–54 | 704 (30.7) |
55–74 | 584 (25.5) |
≥75 | 470 (20.5) |
Male sexb | 1329 (58.1) |
Community type | |
Metro | 1753 (76.6) |
Urban/rural | 332 (14.5) |
Rural | 173 (7.6) |
Remote | 32 (1.4) |
Birthplacec | |
Canada | 588 (26.3) |
Foreign-born by continentd | |
Asia | 1437 (87.6) |
Africa | 79 (4.8) |
Europe | 69 (4.2) |
Americas | 45 (2.7) |
Oceania | 11 (0.7) |
Time in Canada, ye | |
<5 | 456 (28.6) |
≥5 | 1141 (71.4) |
Disease site | |
Respiratory | 1767 (77.2) |
Nonrespiratory | 363 (15.9) |
Respiratory and ronrespiratory | 160 (7.0) |
Positive respiratory smear resultsf | 1152 (62.1) |
Cavitary disease present | 315 (13.8) |
Drug susceptibility | |
MDR | 18 (0.8) |
INH-R (non-MDR) | 173 (7.6) |
HIV status | |
Infected | 103 (4.5) |
Uninfected | 1784 (77.9) |
Unknown | 403 (17.6) |
Illicit drug use | |
Yes | 130 (5.7) |
No | 1639 (71.6) |
Unknown | 521 (22.8) |
Alcohol misuse | |
Yes | 125 (5.5) |
No | 1656 (72.3) |
Unknown | 509 (22.2) |
Material deprivation indexg | |
Quintile 1 (least deprivation) | 273 (12.5) |
Quintile 2 | 418 (19.2) |
Quintile 3 | 529 (24.3) |
Quintile 4 | 529 (24.3) |
Quintile 5 (most deprivation) | 427 (19.6) |
Abbreviations: HIV, human immunodeficiency virus; INH-R, isoniazid resistant; MDR, multidrug- resistant tuberculosis (resistant to isoniazid and rifampin).
aPercentages have been rounded and may not total 100%.
bOne transgender/gender-unknown patient excluded from analysis.
cData unavailable in 57 patients.
dData unavailable in 4 patients.
eData unavailable in 48 patients.
f“Other respiratory” sites (eg, pleura) were excluded.
gData unavailable in 114 patients.